Project Grant R01DK138248

Award Date 8/1/24
Completion Date 5/31/29
Dollars Obligated $1.9M
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Storrs, CT 06269, USA
Similar Awards
This federal Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the Research and Training in Complementary and Integrative Health (CFDA 93.213) program, provides $762,489 to Yale University to evaluate the feasibility, acceptability, adherence, safety, and potential implementation barriers of a home-based transcutaneous auricular vagus nerve stimulation (TAVNS) intervention for pain and symptom management among young adults (18-29 years old)...
This Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $451,297 to the University of Louisville to investigate the use of Gastric Electrical Stimulation (GES) for treating abdominal pain in patients with gastroparesis. The project aims to evaluate two novel parameter settings for the Enterra GES device - one derived from preclinical studies (PP) and one modified from the...
This Project Grant award of $1,461,766.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will fund research on the molecular and cellular mechanisms underlying visceral pain and cross-organ sensitization. The research will focus on understanding the role of MRGPRB2+ mast cell-TRPV1+ nociceptor clusters in bladder pain and bladder-colon cross-sensitization. Key...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $2,884,007 to the University of California, San Diego (UCSD) to investigate mechanisms of intra- and inter-individual pain variability in patients with comorbid chronic low back pain (CLBP) and major depressive disorder (MDD). The research aims to generate individualized prediction models of momentary pain intensity using ecological momentary...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
The U.S. National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,643,228 Cooperative Agreement grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Worcester Polytechnic Institute (WPI) to develop an Integrative Mindfulness-Based Predictive Approach for Chronic Low Back Pain Treatment (IMPACT). The key objectives of this 2-year IMPACT project are to: 1) Initiate a clinical trial of Mindfulness-Based Stress Reduction (MBSR) for chronic low back pain...
This $4.7 million project grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke will support the development of electrophysiological and ultrasound quantitative biomarkers for myofascial pain syndrome. The grant to Beth Israel Deaconess Medical Center will establish the use of electrical impedance myography, myofiber threshold tracking excitability testing, and ultrasound shear wave elastography to assess differences between patients with active...
The federal Project Grant award R01DK142845, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research on the interplay between brain oxytocin and corticotropin-releasing factor (CRF) systems in stress-related visceral analgesia versus hyperalgesia, and its implications for irritable bowel syndrome (IBS). The $647,290 award, with a project period from Jul...
This federal Project Grant award of $726,140.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant aims to elucidate the neural circuits and cellular mechanisms underlying visceral pain processing in the spinal cord and brainstem, with the goal of advancing understanding and treatment of visceral pain conditions such as irritable bowel syndrome,...
This $408,000 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to provide a comprehensive EEG profile of the cortical activity underlying the cognitive processing of the sensory-discriminative and affective-motivational dimensions of osteoarthritis knee pain. The research, conducted by Tarleton State University,...

OBJECTIVE INTEGRATED MULTIMODAL ELECTROPHYSIOLOGICAL INDEX FOR THE QUANTIFICATION OF VISCERAL PAIN - PROJECT SUMMARY/ABSTRACT VISCERAL PAIN IS THE CARDINAL COMPLAINT OF PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS), AN AFFLICTION OF APPROXIMATELY 20% OF THE U.S. POPULATION. DRUGS TO TREAT VISCERAL PAIN ARE LIMITED, WITH SIDE EFFECTS USUALLY OUTWEIGHING ANALGESIC BENEFITS. THE DEVELOPMENT OF EFFECTIVE TREATMENTS FOR IBS IS HAMPERED BY THE LACK OF A RELIABLE BIOMARKER THAT QUANTIFIES THE LEVEL OF VISCERAL PAIN. CLINICAL TRIALS OF PAIN-MANAGING DRUGS RELY ON PATIENT REPORTED PAIN LEVEL, A SUBJECTIVE ASSESSMENT WITH A STRONG PLACEBO EFFECT. THIS HAS RESULTED IN CHALLENGES IN CLINICAL TRIALS FOR THE TESTED DRUGS TO SIGNIFICANTLY OUT-PERFORM THE PLACEBO IN MANAGING VISCERAL PAIN. THUS, AN OBJECTIVE INTEGRATED MULTIMODAL ELECTROPHYSIOLOGICAL INDEX THAT QUANTIFIES THE LEVEL OF VISCERAL PAIN IS MUCH NEEDED IN DEVELOPING NOVEL THERAPIES, ESPECIALLY NON-DRUG TREATMENTS IN MANAGING IBS PAIN. THE AUTONOMIC NERVOUS SYSTEM (ANS) IS THE PRIMARY PATHWAY IN BRAIN-GUT COMMUNICATION, AND IT SIGNIFICANTLY OVERLAPS WITH THE NEURAL CIRCUITRY FOR DETECTING AND PERCEIVING PAIN FROM THE VISCERA. OUR PRELIMINARY DATA HAVE SHOWN CLOSE CORRELATION BETWEEN ANS ACTIVITIES AND SUBJECT-REPORTED PAIN RESPONSES TO NOXIOUS SOMATIC AND VISCERAL STIMULI. COMPARED WITH HEALTHY SUBJECTS, IBS PATIENTS SHOW AN UNCHECKED PREDOMINANCE OF SYMPATHETIC ACTIVITIES AND DESENSITIZED PARASYMPATHETIC ACTIVITIES. ALSO, THE AMOUNT OF ABDOMINAL MUSCLE CONTRACTION, MEASURED BY ELECTROMYOGRAM (EMG), HAS BEEN ESTABLISHED AS A METRIC TO DIFFERENTIATE IBS FROM CONTROL POPULATIONS IN PRECLINICAL STUDIES. THUS, THE ANS AND ABDOMINAL MUSCULAR ACTIVITIES ARE PROMISING TARGETS FOR DEVELOPING OBJECTIVE BIOMARKERS FOR IBS PAIN. WE AIM TO LEVERAGE OUR RECENT TECHNICAL ADVANCES IN WEARABLE SENSING OF ELECTROPHYSIOLOGICAL SIGNALS AND TELEMETRIC TECHNOLOGY TO DEVELOP A ROBUST, SENSITIVE, AND OBJECTIVE BIOMARKER THAT QUANTIFIES THE LEVEL OF VISCERAL PAIN THROUGH NONINVASIVE RECORDINGS OF ELECTRODERMAL ACTIVITIES (EDA), ELECTROCARDIOGRAM (ECG), AND EMG. TWO SPECIFIC AIMS ARE PROPOSED. SPECIFIC AIM 1 WILL USE MACHINE LEARNING TO ESTABLISH AN OBJECTIVE INTEGRATED MULTIMODAL ELECTROPHYSIOLOGICAL (OIME) INDEX BASED ON EDA, ECG, AND ABDOMINAL EMG FOR PAIN QUANTIFICATION AND CLUSTERING OF IBS PATIENTS. SPECIFIC AIM 2 WILL THE INTEGRATED OIME INDEX AS A BIOMARKER TO RELIABLY QUANTIFY VISCERAL PAIN IN IBS PATIENTS AND STRATIFY THE IBS POPULATION. IF SUCCESSFUL, WE WILL ESTABLISH THE OIME INDEX FROM ABDOMINAL BELT-WORN RECORDINGS OF EDA, ECG, AND EMG AS A SENSITIVE AND ROBUST BIOMARKER FOR IBS-RELATED VISCERAL PAIN, WHICH WILL LEAD TO ACCELERATED DEVELOPMENT OF PREVENTIVE AND THERAPEUTIC SCHEMES, ESPECIALLY NONOPIOID TREATMENT FOR EFFECTIVE PAIN MANAGEMENT IN IBS.

Posted 7/29/24, 12:00 AM